11
Jun 24
Online medicine sales and the processing of purchase data: The Court of Justice of the European Union rules
Data related to purchasing non-prescription medicine sold online by an authorized pharmacy should not be considered health-related data under the GDPR.
23
Apr 24
Italian Data Protection Authority publishes rules for platforms (websites or apps) connecting patients and healthcare professionals
The evolution of online platforms and apps that connect patients with healthcare professionals has made medical care more accessible, but it has also raised important issues concerning privacy and the protection of personal data.
17
Jan 24
Artificial intelligence and health care: News and issues in light of guidance from the Italian Data Protection Authority and the WHO
The use of AI in the healthcare field could facilitate improvement of treatment and prevention, and result in more effective allocation of resources in the field. However, there is trepidation about the consequences of possible errors and incorrect use.
19
Jun 23
Processing health data on online platforms: The Garante rules on fairness
With order no. 368 of November 10, 2022, the Italian Data Protection Authority ruled that the provider of an online platform aimed at connecting healthcare professionals with patients was in breach of the personal data protection rules provided by the GDPR in processing data via their platform.
6
Dec 22
Reuse of personal data for research purposes in light of the most recent guidelines from the Garante
In the context of clinical studies, companies are concerned about the legal conditions for use for research purposes of previously collected personal data, including data from third parties.
6
Oct 22
In a first, the European Commission blocks a below-threshold transaction under the EU Merger Regulation (Grail/Illumina)
On September 6, 2022, the European Commission (the “Commission”) blocked the acquisition of Grail by Illumina—although the deal didn’t meet the turnover threshold of the EU or any Member State—arguing that the merger would have prevented innovation and competition in the blood-based early cancer detection test market.
